908 Devices appoints Repligen CEO Tony J. Hunt to Board, effective March 2, 2022

908 Devices Inc.

Tony J. Hunt, President and CEO of Repligen (RGEN), appointed to Board expanding from 8 to 9 directors.
Class II director with term expiring at June 2022 annual meeting; receives $40K annual cash retainer.
One-time initial equity award of $200K (50% RSUs, 50% NQSOs) vesting over three years.
Also eligible for future annual equity awards of $135K on same terms as other non-employee directors.
Hunt brings over 20 years bioprocessing experience; previously President of Bioproduction at Life Technologies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tony J. Hunt

Director

MASS · 908 Devices Inc.

Effective: 2022-03-02
Filed: March 2, 2022, 6:59 PM ET

On March 2, 2022, Tony J. Hunt was appointed to the Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tony J. Hunt was appointed as Director at 908 Devices Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 2, 2022, Tony J. Hunt was appointed to the Board of Directors

View on SEC.gov

908 Devices Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-029353

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.